Zymedyne Therapeutics is pleased to announce that a Mitacs Accelerate Industrial Postdoc has been awarded to Dr Ketul Patel to conduct structure-activity relationship studies and assess the molecular properties of Zymedyne’s lead molecules. Using organic synthesis and medicinal chemistry, Ketul’s work will also help develop new drugs with improved potency, specificity, and commercial potential.
The Mitacs Accelerate Industrial Postdoc, together with the partnering company, provides up to three years of funding – valued at up to $60,000 per year. For more information, please visit:
https://www.mitacs.ca/en/programs/accelerate/industrial-postdoc
